A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
about
PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptorsProstacyclin-dependent apoptosis mediated by PPAR deltaCytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedioneNuclear receptor corepressorsNuclear receptor corepressor RIP140 regulates fat accumulationSMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasisNuclear receptor corepressors and PPARgammaThe amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesPeroxisomal bifunctional enzyme binds and activates the activation function-1 region of the peroxisome proliferator-activated receptor alphaInhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiationIncreased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells.Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane. Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor gamma.Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.A Dominant-Negative PPARgamma Mutant Promotes Cell Cycle Progression and Cell Growth in Vascular Smooth Muscle CellsSpecific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cellsInhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells.In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.Ligand binding and activation of PPARγ by Firemaster® 550: effects on adipogenesis and osteogenesis in vitro15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma.Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activityThe tailless nuclear receptor acts as a dedicated repressor in the early Drosophila embryoNovel insulin sensitizers: pharmacogenomic aspects.Overexpression of dominant negative peroxisome proliferator-activated receptor-γ (PPARγ) in alveolar type II epithelial cells causes inflammation and T-cell suppression in the lung.The NR4A2 nuclear receptor is recruited to novel nuclear foci in response to UV irradiation and participates in nucleotide excision repairThe optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2.Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal cellsIn vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancerNitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARγ-dependent transcription by distinct signaling pathways and with significantly different potencies.Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes.Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer.PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.Airway epithelial cell PPARγ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice.Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells
P2860
Q24290950-E7477FB0-BA36-4C3F-A927-B86428F50DABQ24291677-1C3E928A-F4CC-4319-9957-71A9AC8E63A1Q24307812-877C8B41-7E3E-4989-ABA6-C339DDEA2F8FQ24540376-F778B1DB-B135-44D5-BC1C-869EE93BE80CQ24561531-F5A97CC7-B6C7-41A1-8023-2F0AD4A764D1Q24647529-F3EB2624-FA8C-4875-B327-DF940CEB3274Q25257827-3C69328E-2A9B-4EFD-9BE0-F8A0C1749D71Q28217144-57020007-2B6C-4933-99CE-98E584AF309EQ28221639-ABD9D12E-6034-4E8B-BD5F-0D8AC18872F9Q28345519-5DF742E9-8A85-4592-BD1F-494CC3D771C9Q28507361-EED8710C-AC07-422A-AF77-B8E9B10FE77FQ30433046-897D6BCC-52A4-4F97-AFED-79F5576BB68CQ31743193-2460C1E4-CDF7-4B5F-AA3C-947BC8EFE583Q33642252-65CDB569-46E5-4828-8A85-66092517DD56Q33724886-86373CEC-6448-4CFB-867E-0D2D2A76F7E2Q33809071-ED52861F-15BD-493B-9649-DFA0FE9A33ADQ33817896-A89BFAA0-1099-46F0-8ED4-89553FD504E4Q33967999-2798EFCA-DD06-4B5B-94BA-DCCB2B994134Q33993702-836EA8AA-7074-4BE1-9483-A9AD94BB0B9AQ34155250-99156EED-7211-479A-B454-35A564FA7BC8Q34360082-E6C3C9AB-BB47-48B9-A617-8938CA0FC44EQ34435425-AF7B5ADE-EF8C-4D48-B668-BB0C0E864782Q34523177-F0D8870D-69B8-4E21-8E54-58AE59E4BE70Q34524549-A3336188-07D8-4F47-BA4B-3DD50B0B36CAQ34564826-4459E307-DE95-497C-A7BF-F0ABFD314620Q34609164-A63CE1E7-CC18-4E60-AC98-471C4E8D4E06Q34838708-6E9C5860-301B-4239-BC6F-2F20FEF3C22EQ35040153-562B7E49-D5AC-4567-A982-BACAA7F82963Q35055598-2503C7B9-2B41-449D-8171-52DE59789A78Q35161441-C8D12524-7E28-4D82-AC9C-C7809541F5C3Q35168034-483502E1-1CDB-4525-961F-6B85B7EBBAA1Q35201387-4388CA3E-A6E2-451E-A223-E9AB1F5A0775Q35222158-7B5C2EDB-58A4-4271-8EBC-097C12F02596Q35639785-C376E5D8-4ED2-479E-BFEF-EAF83106A92EQ35641787-26708739-9DDC-4423-AA84-2C6A967533C5Q35677716-2EA1F780-50B6-4D0C-AED3-DA65750FE419Q35714424-540DF37B-D8A4-42EF-A136-B00AB00C3C1FQ35744022-9620D0C7-0814-4643-B72D-D3576786029FQ35916876-9956955B-01BA-4C88-87CD-798B6FF56DFBQ36099516-E6B4951E-D634-4BD6-AB0E-E32DF3FB353B
P2860
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
A dominant-negative peroxisome ...... ARgamma-mediated adipogenesis.
@en
type
label
A dominant-negative peroxisome ...... ARgamma-mediated adipogenesis.
@en
prefLabel
A dominant-negative peroxisome ...... ARgamma-mediated adipogenesis.
@en
P2093
P356
P1476
A dominant-negative peroxisome ...... ARgamma-mediated adipogenesis.
@en
P2093
C Provenzano
J M Wentworth
J W Schwabe
M Agostini
O Rajanayagam
P O Browne
T N Collingwood
P304
P356
10.1074/JBC.275.8.5754
P407
P577
2000-02-01T00:00:00Z